RPAM
ICPT

Rhenman & Partners Asset Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Rhenman & Partners Asset Management’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-40,000
Closed -$2.52M – 98
2020
Q1 		$2.52M Hold
40,000
– – 0.35% 71
2019
Q4 		$4.96M Sell
40,000
-7,600
-16% -$680K 0.54% 65
2019
Q3 		$3.16M Buy
47,600
+10,000
+27% +$672K 0.4% 66
2019
Q2 		$2.99M Buy
+37,600
New +$3.37M 0.33% 67
2018
Q1 		– Sell
-38,500
Closed -$2.25M – 100
2017
Q4 		$2.25M Sell
38,500
-1,500
-4% -$94.6K 0.3% 71
2017
Q3 		$2.32M Buy
40,000
+36,992
+1,230% +$3.98M 0.3% 74
2017
Q2 		$364K Sell
3,008
-26,992
-90% -$3.13M 0.05% 96
2017
Q1 		$3.39M Buy
30,000
+10,000
+50% +$1.17M 0.54% 65
2016
Q4 		$2.17M Buy
20,000
+10,000
+100% +$1.19M 0.42% 70
2016
Q3 		$1.65M Buy
+10,000
New +$1.58M 0.26% 84
2016
Q1 		– Sell
-26,000
Closed -$3.88M – 96
2015
Q4 		$3.88M Sell
26,000
-6,000
-19% -$1.02M 0.59% 59
2015
Q3 		$5.31M Buy
32,000
+8,000
+33% +$1.76M 0.85% 47
2015
Q2 		$5.79M Buy
24,000
+1,000
+4% +$266K 0.7% 47
2015
Q1 		$6.49M Buy
23,000
+1,000
+5% +$217K 1.09% 34
2014
Q4 		$3.43M Buy
22,000
+3,400
+18% +$628K 0.99% 35
2014
Q3 		$4.4M Buy
+18,600
New +$4.74M 1.29% 26

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Rhenman & Partners Asset Management's ICPT Position: Q2 2020 in Review

Rhenman & Partners Asset Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q2 2020, closing a stake of 40,000 shares — an estimated $2.52M sold.

Rhenman & Partners Asset Management first reported a position in ICPT in Q3 2014 and held it in 16 quarters. The position peaked at $6.49M in Q1 2015. 192 funds tracked by Wall St. Rank hold ICPT as of Q2 2020.

  • Rhenman & Partners Asset Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q2 2020 after selling out during the quarter.
  • Rhenman & Partners Asset Management sold 40,000 Intercept Pharmaceuticals, Inc. shares in Q2 2020, an estimated $2.52M.
  • Rhenman & Partners Asset Management first reported a position in Intercept Pharmaceuticals, Inc. in Q3 2014 and held it in 16 quarters.
  • Rhenman & Partners Asset Management's Intercept Pharmaceuticals, Inc. position peaked at $6.49M in Q1 2015.
  • 192 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q2 2020.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2020, filed 16 Jul 2020.